pbabe puro erbb2 wt Search Results


erbb2 l755s c.2264t>c  (BioInnovatise Inc)
90
BioInnovatise Inc erbb2 l755s c.2264t>c
<t>ERBB2</t> mutations occur in a variety of cancer types with mutational hotspots occurring across the receptor. (A and B) Bar plot of weighted averages of ERBB2 mutations (A) and ERBB2 exon 20 mutation (B) frequency by cancer. Bars are representative of the weighted average ± SEM. Dot sizes are representative of number of cases in each database. Frequency of ERBB2 mutations detected by cfDNA reported by Guardant Health were normalized for clinical sensitivity as reported in Odegaard et al 2018 (Odegaard et al., 2018). See also Table S1.
Erbb2 L755s C.2264t>C, supplied by BioInnovatise Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/erbb2 l755s c.2264t>c/product/BioInnovatise Inc
Average 90 stars, based on 1 article reviews
erbb2 l755s c.2264t>c - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


ERBB2 mutations occur in a variety of cancer types with mutational hotspots occurring across the receptor. (A and B) Bar plot of weighted averages of ERBB2 mutations (A) and ERBB2 exon 20 mutation (B) frequency by cancer. Bars are representative of the weighted average ± SEM. Dot sizes are representative of number of cases in each database. Frequency of ERBB2 mutations detected by cfDNA reported by Guardant Health were normalized for clinical sensitivity as reported in Odegaard et al 2018 (Odegaard et al., 2018). See also Table S1.

Journal: Cancer cell

Article Title: Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity

doi: 10.1016/j.ccell.2019.09.001

Figure Lengend Snippet: ERBB2 mutations occur in a variety of cancer types with mutational hotspots occurring across the receptor. (A and B) Bar plot of weighted averages of ERBB2 mutations (A) and ERBB2 exon 20 mutation (B) frequency by cancer. Bars are representative of the weighted average ± SEM. Dot sizes are representative of number of cases in each database. Frequency of ERBB2 mutations detected by cfDNA reported by Guardant Health were normalized for clinical sensitivity as reported in Odegaard et al 2018 (Odegaard et al., 2018). See also Table S1.

Article Snippet: ERBB2 L755S c.2264T>C , Created by Bioinnovatise from pBabe-puro ERBB2 WT from Addgene (#40978) , .

Techniques: Mutagenesis

ERBB2 mutation hotspots vary by cancer type. (A-B) Frequency and location of ERBB2 mutations found across all cancers analyzed by protein coding region (A) and specific variant frequency of top ten variants (B) (n = 2338). (C-D) Frequency and location of ERBB2 mutations found in NSCLC (n = 177) analyzed by protein coding region (C) and specific variant (D). (E-F) Frequency and location of ERBB2 mutations found in breast cancer (n = 143) analyzed by protein coding region (E) and specific variant (F). (G-H) Frequency and location of ERBB2 mutations found in colon cancer (n = 219) analyzed by protein coding region (G) and specific variant (H). (B, D, F, and H) Length of bars on lollipop plots are relative to frequency of mutation reported. See also Figure S1.

Journal: Cancer cell

Article Title: Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity

doi: 10.1016/j.ccell.2019.09.001

Figure Lengend Snippet: ERBB2 mutation hotspots vary by cancer type. (A-B) Frequency and location of ERBB2 mutations found across all cancers analyzed by protein coding region (A) and specific variant frequency of top ten variants (B) (n = 2338). (C-D) Frequency and location of ERBB2 mutations found in NSCLC (n = 177) analyzed by protein coding region (C) and specific variant (D). (E-F) Frequency and location of ERBB2 mutations found in breast cancer (n = 143) analyzed by protein coding region (E) and specific variant (F). (G-H) Frequency and location of ERBB2 mutations found in colon cancer (n = 219) analyzed by protein coding region (G) and specific variant (H). (B, D, F, and H) Length of bars on lollipop plots are relative to frequency of mutation reported. See also Figure S1.

Article Snippet: ERBB2 L755S c.2264T>C , Created by Bioinnovatise from pBabe-puro ERBB2 WT from Addgene (#40978) , .

Techniques: Mutagenesis, Variant Assay

MDS of HER2 mutants reveal possible mechanisms for decreased drug sensitivity for Y772dupYVMA and L755P mutations. (A) αC-helix positions for the HER2 V777L and Y772dupYVMA exon 20 mutants during the 150 ns accelerated MDS. (B) Fractional population of molecular dynamics snapshots for the HER2 exon 20 mutants in the αC-helix “in” vs. “out” conformations. (C) Molecular dynamics snapshots of the V777L (white backbone, light green P-loop) and Y772dupYVMA (grey backbone, dark green P-loop) mutants. Note minor differences in P-loop and kinase hinge conformations but a significant shift in αC-helix position (“out” position for V777L in blue, “in” position for Y772dupYVMA in purple). (D) Binding pocket volume profiles for the HER2 mutants taken from the accelerated MDS. (E) Molecular dynamics snapshots of L755P (white, backbone; light green, P-loop; yellow, hinge; blue, αC-helix) and L755S (grey, backbone; dark green, P-loop; orange, hinge; purple, αC-helix) HER2 mutants. (F) Bar plots of IC50 values of HER2 mutants with binding pocket volumes ≥ WT HER2 or smaller than WT HER2 treated with quinazoline or indole based TKIs. Bars are representative of mean ± SEM (n ≥ 3). See also Figure S4.

Journal: Cancer cell

Article Title: Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity

doi: 10.1016/j.ccell.2019.09.001

Figure Lengend Snippet: MDS of HER2 mutants reveal possible mechanisms for decreased drug sensitivity for Y772dupYVMA and L755P mutations. (A) αC-helix positions for the HER2 V777L and Y772dupYVMA exon 20 mutants during the 150 ns accelerated MDS. (B) Fractional population of molecular dynamics snapshots for the HER2 exon 20 mutants in the αC-helix “in” vs. “out” conformations. (C) Molecular dynamics snapshots of the V777L (white backbone, light green P-loop) and Y772dupYVMA (grey backbone, dark green P-loop) mutants. Note minor differences in P-loop and kinase hinge conformations but a significant shift in αC-helix position (“out” position for V777L in blue, “in” position for Y772dupYVMA in purple). (D) Binding pocket volume profiles for the HER2 mutants taken from the accelerated MDS. (E) Molecular dynamics snapshots of L755P (white, backbone; light green, P-loop; yellow, hinge; blue, αC-helix) and L755S (grey, backbone; dark green, P-loop; orange, hinge; purple, αC-helix) HER2 mutants. (F) Bar plots of IC50 values of HER2 mutants with binding pocket volumes ≥ WT HER2 or smaller than WT HER2 treated with quinazoline or indole based TKIs. Bars are representative of mean ± SEM (n ≥ 3). See also Figure S4.

Article Snippet: ERBB2 L755S c.2264T>C , Created by Bioinnovatise from pBabe-puro ERBB2 WT from Addgene (#40978) , .

Techniques: Binding Assay

Human cell lines expressing HER2 mutants are also sensitive to poziotinib. (A-C) Dose response curves of MCF10A cells expressing HER2 exon 20 insertion mutants G776delinsVC (A), Y772dupYVMA (B), or G778dupGSP (C), treated with indicated TKIs for 72 hr. (D) Dot plot of ratio of IC50 values comparing MCF10A expressing HER2 exon 20 mutants to MCF10A expressing WT HER2. Dots are representative of mean ± SEM for each cell line and bars are representative of mean ± SEM of all three cell lines (n ≥ 3 for each cell line). (E) Dose response curve of CW-2 colorectal cancer cell line harboring endogenous ERBB2 exon 19 mutation, L755S, treated with indicated inhibitors for 72 hr. (A-C, E) Curves are representative of mean ± SEM, n = 3. (F) Bar graph of CW-2 tumor volume at day 21. Tumors were randomized at 350 mm3, indicated by the dotted line. Dots are representative of individual tumors (n = 5/ group), and bars are representative of mean ± SEM. See also Figure S5.

Journal: Cancer cell

Article Title: Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity

doi: 10.1016/j.ccell.2019.09.001

Figure Lengend Snippet: Human cell lines expressing HER2 mutants are also sensitive to poziotinib. (A-C) Dose response curves of MCF10A cells expressing HER2 exon 20 insertion mutants G776delinsVC (A), Y772dupYVMA (B), or G778dupGSP (C), treated with indicated TKIs for 72 hr. (D) Dot plot of ratio of IC50 values comparing MCF10A expressing HER2 exon 20 mutants to MCF10A expressing WT HER2. Dots are representative of mean ± SEM for each cell line and bars are representative of mean ± SEM of all three cell lines (n ≥ 3 for each cell line). (E) Dose response curve of CW-2 colorectal cancer cell line harboring endogenous ERBB2 exon 19 mutation, L755S, treated with indicated inhibitors for 72 hr. (A-C, E) Curves are representative of mean ± SEM, n = 3. (F) Bar graph of CW-2 tumor volume at day 21. Tumors were randomized at 350 mm3, indicated by the dotted line. Dots are representative of individual tumors (n = 5/ group), and bars are representative of mean ± SEM. See also Figure S5.

Article Snippet: ERBB2 L755S c.2264T>C , Created by Bioinnovatise from pBabe-puro ERBB2 WT from Addgene (#40978) , .

Techniques: Expressing, Mutagenesis

Patients with NSCLC harboring ERBB2 mutations had a 42% confirmed response rate to poziotinib. (A) Waterfall plot of the objective responses of patients on clinical trial . Objective PR are shown in dark green, an unconfirmed response is shown in light green, SD is shown in yellow, and PD is shown in red. (B) Kaplan-meier plot of PFS of the 12 patients in (A). (C) Computed tomography (CT) scan of a patient with an ERBB2 Y772dupYVMA mutation one day before and eight weeks after poziotinib treatment. Blue arrow indicates the target lesion and the red arrow indicates the resolved pleural effusion. (D) Positron emission tomography (PET) scans of patient with ERBB2 L755P mutant NSCLC one day before and four weeks after poziotinib treatment. White boxes highlight the lesion of interest. See also Figure S6.

Journal: Cancer cell

Article Title: Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity

doi: 10.1016/j.ccell.2019.09.001

Figure Lengend Snippet: Patients with NSCLC harboring ERBB2 mutations had a 42% confirmed response rate to poziotinib. (A) Waterfall plot of the objective responses of patients on clinical trial . Objective PR are shown in dark green, an unconfirmed response is shown in light green, SD is shown in yellow, and PD is shown in red. (B) Kaplan-meier plot of PFS of the 12 patients in (A). (C) Computed tomography (CT) scan of a patient with an ERBB2 Y772dupYVMA mutation one day before and eight weeks after poziotinib treatment. Blue arrow indicates the target lesion and the red arrow indicates the resolved pleural effusion. (D) Positron emission tomography (PET) scans of patient with ERBB2 L755P mutant NSCLC one day before and four weeks after poziotinib treatment. White boxes highlight the lesion of interest. See also Figure S6.

Article Snippet: ERBB2 L755S c.2264T>C , Created by Bioinnovatise from pBabe-puro ERBB2 WT from Addgene (#40978) , .

Techniques: Computed Tomography, Mutagenesis, Positron Emission Tomography

Poziotinib treatment induces accumulation of HER2 on the cell surface, and combination of poziotinib and T-DM1 treatment potentiates anti-tumor activity. (A) FACS analysis of HER2 expression on MCF10A cells expressing indicated HER2 mutants or WT HER2 after 24 hr of 10 nM poziotinib treatment. (B) Representative western blot of ubiquitin and total HER2 after immunoprecipitation of HER2 in MCF10A cells expressing WT HER2 or indicated HER2 mutants. Molecular weight ladder run between samples was omitted as indicated by the white space between lanes. Ubiquitin level was normalized to HER2 level then to DMSO control to determine fold change in relative ubiquitin expression (C) Bar plot of T-DM1 IC50 values of MCF10A cells expressing indicated HER2 mutants treated with T-DM1 alone or in combination with poziotinib. (n = 2), *, p < 0.0001. (D) Tumor growth curves of ERBB2 Y772dupYVMA NSCLC PDX treated with the indicated inhibitors. (E) Dot plot of percent change in tumor volume of mice treated with indicated inhibitors at day 15. (A-E) Bars and symbols are representative of mean ± SEM. (F) Kaplan-Meier curve of PFS of mice bearing ERBB2 Y772dupYVMA PDX treated with indicated inhibitors. (G) Summary of number of tumor bearing mice in each group at day 15 and day 45. (H) ERBB2 Y772dupYVMA GEMM were treated with indicated inhibitors for four weeks and tumor volume was determined by MRI. Bars are representative of individual mouse tumor volume. (I) Percent change in body weight for ERBB2 GEMMs over the first 14 days of treatment with indicated inhibitors. Symbols are representative of mean body weight ± SEM. See also Figure S7.

Journal: Cancer cell

Article Title: Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity

doi: 10.1016/j.ccell.2019.09.001

Figure Lengend Snippet: Poziotinib treatment induces accumulation of HER2 on the cell surface, and combination of poziotinib and T-DM1 treatment potentiates anti-tumor activity. (A) FACS analysis of HER2 expression on MCF10A cells expressing indicated HER2 mutants or WT HER2 after 24 hr of 10 nM poziotinib treatment. (B) Representative western blot of ubiquitin and total HER2 after immunoprecipitation of HER2 in MCF10A cells expressing WT HER2 or indicated HER2 mutants. Molecular weight ladder run between samples was omitted as indicated by the white space between lanes. Ubiquitin level was normalized to HER2 level then to DMSO control to determine fold change in relative ubiquitin expression (C) Bar plot of T-DM1 IC50 values of MCF10A cells expressing indicated HER2 mutants treated with T-DM1 alone or in combination with poziotinib. (n = 2), *, p < 0.0001. (D) Tumor growth curves of ERBB2 Y772dupYVMA NSCLC PDX treated with the indicated inhibitors. (E) Dot plot of percent change in tumor volume of mice treated with indicated inhibitors at day 15. (A-E) Bars and symbols are representative of mean ± SEM. (F) Kaplan-Meier curve of PFS of mice bearing ERBB2 Y772dupYVMA PDX treated with indicated inhibitors. (G) Summary of number of tumor bearing mice in each group at day 15 and day 45. (H) ERBB2 Y772dupYVMA GEMM were treated with indicated inhibitors for four weeks and tumor volume was determined by MRI. Bars are representative of individual mouse tumor volume. (I) Percent change in body weight for ERBB2 GEMMs over the first 14 days of treatment with indicated inhibitors. Symbols are representative of mean body weight ± SEM. See also Figure S7.

Article Snippet: ERBB2 L755S c.2264T>C , Created by Bioinnovatise from pBabe-puro ERBB2 WT from Addgene (#40978) , .

Techniques: Activity Assay, Expressing, Western Blot, Ubiquitin Proteomics, Immunoprecipitation, Molecular Weight, Control

KEY RESOURCES TABLE

Journal: Cancer cell

Article Title: Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity

doi: 10.1016/j.ccell.2019.09.001

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: ERBB2 L755S c.2264T>C , Created by Bioinnovatise from pBabe-puro ERBB2 WT from Addgene (#40978) , .

Techniques: Recombinant, In Vitro, In Vivo, Synthesized, Immunoprecipitation, Enzyme-linked Immunosorbent Assay